

Corporate Medical Policy: Place of Service for Medical Infusions

Related Corporate Medical Policies with Applicable Restricted Product(s):

- Abatacept (Orencia®)
- Alpha 1-Antitrypsin Inhibitor Therapy
- Anifrolumab-fnia (Saphnelo™)
- Belimumab (Benlysta®)
- Burosumab-twza (Crysvita®)
- Canakinumab (Ilaris®)
- Certolizumab pegol (Cimzia®)
- Crizanlizumab-tmca (Adakveo®)
- Eculizumab (Soliris®)
- Edaravone (Radicava®)
- Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders
- Eptinezumab-jjmr (Vyepi™)
- Evinacumab-dgnb (Evkeeza™)
- Fosdenopterin (Nulibry™)
- Givosiran (Givlaari®)
- Golimumab (Simponi Aria®)
- Guselkumab (Tremfya®)
- Ibalizumab-uiyk (Trogarzo®)
- Immunoglobulin Therapy
- Inclisiran (Leqvio®)
- Inebilizumab-cdon (Uplizna™)
- Infliximab (Remicade®) and Infliximab Biosimilars
- Interleukin-5 Antagonists
- Letermovir (Prevymis™)
- Lumasiran (Oxlumo™)
- Luspatercept-aamt (Reblozyl®)
- Natalizumab (Tysabri®)

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

- Ocrelizumab (Ocrevus®)
- Omalizumab (Xolair®)
- Patisiran (Onpattro®)
- Pegcetacoplan (Empaveli™)
- Plasminogen, human-tvmh (Ryplazim®)
- Ravulizumab-cwvz (Ultomiris®)
- Romiplostim (NPlate®)
- Romosozumab-aqqg (Evenity™)
- Somatostatin Analogs
- Sutimlimab (Enjaymo™)
- Teprotumumab-trbw (Tepezza™)
- Tezepelumab-ekko (Tezspire™)
- Tocilizumab (Actemra®)
- Tildrakizumab-asmn (Ilumya®)
- Treatment of Hereditary Angioedema
- Ustekinumab (Stelara®)
- Vedolizumab (Entyvio®)

****NOTE:** A comprehensive list of the individual restricted products that are applicable to this policy is included below in the “Restricted Product(s) Applicable to Policy” table.

Other Related Corporate Medical Policies:

- Infusion Therapy in the Home
- Private Duty Nursing Services

Rationale:

- Inpatient hospital and outpatient facilities are uniquely equipped to handle and support emergency medical situations. It is appropriate for patients, who are medically unstable and in danger of needing medical services only available in an outpatient hospital setting, to have access to medical injections or infusions in these facilities.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

- For those patients who are considered medically stable, drug injections or infusions may be administered in settings that would be considered less intensive, yet safe and effective alternatives. Acceptable alternative sites of care include non-hospital outpatient centers, physician/professional offices, infusion suites/ambulatory infusion centers, and infusions administered at home.
- Alternative places of service may be more convenient for the patient, less expensive, and lessen risk of exposure to hospital acquired infections.
- Guidelines and agencies support first injections or infusions of most drugs in well-controlled, hospital-based settings. This is to ensure emergency access to care to address serious infusion-associated adverse reactions, such as anaphylaxis or severe hypotension. Research has shown the safety and efficacy of administering subsequent injections or infusions in a less intensive environment, including the home setting.
- ****Please note, this policy specifically applies to the injection or infusion drugs that are addressed separately in individual medical policies as referenced above in the “Restricted Product(s)” section.**

Criteria for Medical Necessity:

Medical injection or infusion therapy of the restricted product(s) in an inpatient or outpatient hospital setting is considered medically necessary when the following criteria are met:

1. For requests for injection or infusion administration in an **inpatient setting**, the injection or infusion may be given if the inpatient admission is NOT for the sole purpose of administering the injection or infusion; **OR**
2. For requests for injection or infusion administration in an **outpatient hospital setting**, the injection or infusion may be given if ONE of the following criteria are met:
 - a. History of a severe adverse event following that injection or infusion (i.e., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure); **OR**
 - b. Conditions that cause an increased risk for severe adverse event (i.e., unstable renal function, cardiopulmonary conditions, unstable vascular access); **OR**
 - c. History of mild adverse events that have not been successfully managed through mild pre-medication (e.g., diphenhydramine, acetaminophen, steroids, fluids, etc.); **OR**
 - d. Inability to physically and cognitively adhere to the treatment schedule and regimen complexity; **OR**
 - e. New to therapy, defined as initial injection or infusion OR less than 3 months since initial injection or infusion; **OR**
 - f. Re-initiation of therapy, defined as ONE of the following:
 - i. First injection or infusion after 6 months of no injections or infusions for drugs with an approved dosing interval less than 6 months duration; **OR**

- ii. First injection or infusion after at least a 1-month gap in therapy outside of the approved dosing interval for drugs requiring every 6 months dosing duration; **OR**
- g. Requirement of a change in the requested restricted product formulation; **AND**
- 3. If the Site of Care Medical Necessity Criteria in #1 or #2 above are not met, the injection or infusion will be administered in a **home-based infusion** or physician office setting with or without supervision by a certified healthcare professional.

Restricted Product(s) Applicable to Policy		
Related Corporate Medical Policy	Medication	HCPCS
Abatacept (Orencia®)	abatacept (Orencia®) intravenous (IV) infusion or subcutaneous (SC) injection	J0129
Alpha 1-Antitrypsin Inhibitor Therapy	alpha1-proteinase inhibitor (human) (Aralast NP™) intravenous (IV) infusion	J0256
	alpha1-proteinase inhibitor (human) (Glassia®) intravenous (IV) infusion	J0257
	alpha1-proteinase inhibitor (human) (Prolastin®-C) intravenous (IV) infusion	J0256
	alpha1-proteinase inhibitor (human) (Zemaira®) intravenous (IV) infusion	J0256
Anifrolumab-fnia (Saphnelo™)	anifrolumab-fnia (Saphnelo™) intravenous (IV) infusion	C9086 J3490* J3590*

Belimumab (Benlysta®)	belimumab (Benlysta®) intravenous (IV) infusion or subcutaneous (SC) injection	J0490
Burosumab-twza (Crysvita®)	burosumab-twza (Crysvita®) subcutaneous (SC) injection	J0584
Canakinumab (Ilaris®)	canakinumab (Ilaris®) subcutaneous (SC) injection	J0638
Certolizumab pegol (Cimzia®)	certolizumab pegol (Cimzia®) subcutaneous (SC) injection	J0717
Crizanlizumab-tmca (Adakveo®)	crizanlizumab-tmca (Adakveo®) intravenous (IV) infusion	J0791
Eculizumab (Soliris®)	eculizumab (Soliris®) intravenous (IV) infusion	J1300
Edaravone (Radicava®)	edaravone (Radicava®) intravenous (IV) infusion	J1301
	laronidase (Aldurazyme®) intravenous (IV) infusion	J1931

Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders	imiglucerase (Cerezyme®) intravenous (IV) infusion	J1786
	idursulfase (Elaprase®) intravenous (IV) infusion	J1743
	taliglucerase alfa (Elelyso®) intravenous (IV) infusion	J3060
	agalsidase beta (Fabrazyme®) intravenous (IV) infusion	J0180
	sebelipase alfa (Kanuma®) intravenous (IV) infusion	J2840
	alglucosidase alfa (Lumizyme®) intravenous (IV) infusion	J0221
	vestronidase alfa-vjvk (Mepsevii™) intravenous (IV) infusion	J3397
	galsulfase (Naglazyme®) intravenous (IV) infusion	J1458

	avalglucosidase alfa-ngpt (Nexviazyme™) intravenous (IV) infusion	C9085 J3490* J3590*
	elosulfase alfa (Vimizim®) intravenous (IV) infusion	J1322
	velaglucerase Alfa (Vpriv®) intravenous (IV) infusion	J3385
Eptinezumab-jjmr (Vyepti™)	eptinezumab-jjmr (Vyepti™) intravenous (IV) infusion	J3032
Evinacumab-dgnb (Evkeeza™)	evinacumab-dgnb (Evkeeza™) intravenous (IV) infusion	J1305
Fosdenopterin (Nulibry™)	fosdenopterin (Nulibry™) intravenous (IV) infusion	C9399* J3490* J3590*
Givosiran (Givlaari®)	givosiran (Givlaari®) subcutaneous (SC) injection	J0223
Golimumab (Simponi Aria®)	golimumab (Simponi Aria®) intravenous (IV) infusion	J1602

Guselkumab (Tremfya®)	guselkumab (Tremfya®) subcutaneous (SC) injection	J1628
Ibalizumab-uiyk (Trogarzo®)	ibalizumab-uiyk (Trogarzo®) intravenous (IV) infusion	J1746
Immunoglobulin Therapy	Asceniv™ intravenous (IV) immune globulin	J1554 J1599 90283
	Bivigam® intravenous (IV) immune globulin	J1556 J1599 90283
	Carimune® NF intravenous (IV) immune globulin	J1566 J1599 90283
	Cutaquig® subcutaneous (SC) immune globulin	C9399* J3490* J3590* 90284
	Cuvitru™ subcutaneous (SC) immune globulin	J1555 90284
	Flebogamma® intravenous (IV) immune globulin	J1572 J1599 90283

	Gammagard S/D® intravenous (IV) immune globulin	J1569 J1566 J1599 90283
	Gammagard™ Liquid intravenous (IV) or subcutaneous (SC) immune globulin	J1569 J1599 90283 90284
	Gammaked™ intravenous (IV) or subcutaneous (SC) immune globulin	J1561 J1599 90283 90284
	Gammaplex® intravenous (IV) immune globulin	J1557 J1599 90283
	Gamunex-C® intravenous (IV) or subcutaneous (SC) immune globulin	J1561 J1599 90283 90284
	Hizentra® subcutaneous (SC) immune globulin	J1559 90284
	HyQvia™ subcutaneous (SC) immune globulin	J1575 90284
	Octagam® intravenous (IV) immune globulin	J1568 J1599 90283

	Panzyga® intravenous (IV) immune globulin	J1599 90283
	Privigen® intravenous (IV) immune globulin	J1459 J1599 90283
	Xembify™ subcutaneous (SC) immune globulin	J1558 90284
Inclisiran (Leqvio®)	inclisiran (Leqvio®) subcutaneous (SC) injection	C9399* J3490* J3590*
Inebilizumab-cdon (Uplizna™)	inebilizumab-cdon (Uplizna™) intravenous (IV) infusion	J1823
Infliximab (Remicade®) and Infliximab Biosimilars	infliximab (Remicade®) intravenous (IV) infusion	J1745
	infliximab-axxq (Avsola™) intravenous (IV) infusion	Q5121
	infliximab-dyyb (Inflectra®) intravenous (IV) infusion	Q5103

	infliximab-abda (Renflexis [®]) intravenous (IV) infusion	Q5104
Interleukin-5 Antagonists	reslizumab (Cinqair [®]) intravenous (IV) infusion	J2786
	benralizumab (Fasenra [®]) subcutaneous (SC) injection	J0517
	mepolizumab (Nucala [®]) subcutaneous (SC) injection	J2182
Letermovir (Prevymis [™])	letermovir (Prevymis [™]) intravenous (IV) infusion	C9399* J3490* J3590*
Lumasiran (Oxlumo [™])	lumasiran (Oxlumo [™]) subcutaneous (SC) injection	J0224
Luspatercept-aamt (Reblozyl [®])	luspatercept-aamt (Reblozyl [®]) subcutaneous (SC) injection	J0896
Natalizumab (Tysabri [®])	natalizumab (Tysabri [®]) intravenous (IV) infusion	J2323

Ocrelizumab (Ocrevus [®])	ocrelizumab (Ocrevus [®]) intravenous (IV) infusion	J2350
Omalizumab (Xolair [®])	omalizumab (Xolair [®]) subcutaneous (SC) injection	J2357
Patisiran (Onpattro [®])	patisiran (Onpattro [®]) intravenous (IV) infusion	J0222
Pegcetacoplan (Empaveli [™])	pegcetacoplan (Empaveli [™]) subcutaneous (SC) infusion	C9399* J3490* J3590*
Plasminogen, human-tvmh (Ryplazim [®])	plasminogen, human-tvmh (Ryplazim [®]) intravenous (IV) infusion	C9399* J3490* J3590*
Ravulizumab-cwvz (Ultomiris [®])	ravulizumab-cwvz (Ultomiris [®]) intravenous (IV) infusion	J1303
Romiplostim (NPlate [®])	romiplostim (NPlate [®]) subcutaneous (SC) injection	J2796
Romozosumab-aqqg (Evenity [™])	romozosumab-aqqg (Evenity [™]) subcutaneous (SC) injection	J3111

Somatostatin Analogs	octreotide (Sandostatin [®]) intravenous (IV) infusion or subcutaneous (SC) injection	J2354
	octreotide (Sandostatin [®] LAR Depot) gluteal intramuscular (IM) injection	J2353
	pasireotide (Signifor [®] LAR) intramuscular (IM) injection	J2502
	lanreotide (Somatuline [®] Depot) subcutaneous (SC) injection	J1930
Sutimlimab (Enjaymo [™])	Sutimlimab (Enjaymo [™]) intravenous (IV) infusion	C9399** J3490** J3590** J9999**
Teprotumumab-trbw (Tepezza [™])	teprotumumab-trbw (Tepezza [™]) intravenous (IV) infusion	J3241
Tezepelumab-ekko (Tezspire [™])	tezepelumab-ekko (Tezspire [™]) subcutaneous (SC) injection	C9399* J3490* J3590*
Tildrakizumab-asmn (Ilumya [®])	tildrakizumab-asmn (Ilumya [®]) subcutaneous (SC) injection	J3245

Tocilizumab (Actemra®)	tocilizumab (Actemra®) intravenous (IV) infusion or subcutaneous (SC) injection	J3262
Treatment of Hereditary Angioedema	C1 esterase inhibitor (Berinert®) intravenous (IV) injection	J0597
	C1 esterase inhibitor (Cinryze®) intravenous (IV) injection	J0598
	icatibant (Firazyr®) subcutaneous (SC) injection	J1744
	ecallantide (Kalbitor®) subcutaneous (SC) injection	J1290
	C1 esterase inhibitor (Ruconest®) intravenous (IV) injection	J0596
Ustekinumab (Stelara®)	ustekinumab (Stelara®) intravenous (IV) infusion or subcutaneous (SC) injection	J3357 J3358
Vedolizumab (Entyvio®)	vedolizumab (Entyvio®) intravenous (IV) infusion	J3380

***Non-specific assigned HCPCS codes, please refer to product NDC**

Other service codes that may be applicable: 86711, 99506, 99601, 99602, S0353, S0354, S5035, S5036, S5497, S5498, S5501, S5502, S5517, S5518, S5520, S5521, S5522, S5523, S9123, S9124, S9208, S9325, S9326, S9327, S9328, S9329, S9330, S9331, S9336, S9338, S9345, S9346, S9347, S9348, S9349, S9351, S9353, S9355, S9357, S9359, S9361, S9363, S9364, S9365, S9366, S9367, S9368, S9370, S9372, S9373, S9374, S9375, S9376, S9377, S9379, S9490, S9494, S9497, S9500, S9501, S9502, S9503, S9504, S9537, S9538, S9542, S9558, S9559, S9810, E0691-E0694

NOTE:

- Charges for routinely included supplies such as gauze, infusion sets, needles, cassettes, tape, cleansing solutions (e.g., betadine, alcohol), heparin and saline flushes, diluents for mixing drugs, and splints are included in the infusion reimbursement.
- Catheter care may be reported separately when used as a stand-alone therapy, or during days not covered under per diem by another therapy. PICC line care will only be allowed as a separate charge if there is no other therapy in the last 30 days in the home.
- Home infusion therapy includes all of the components related to such therapy, such as, but not limited to, nursing services, durable medical equipment, supplies, Prescription and non-Prescription Legend Drugs and solutions, pharmacy compounding and dispensing, specimen collection, patient and family education, delivery of drugs and supplies, and management of emergencies arising from said therapy.

References: all information referenced is from FDA package insert unless otherwise noted below.

Policy Implementation/Update Information

February 2022: Criteria update: Added the following drugs and HCPCS codes for clarity, with criteria also available in individual policies: Nexvazyme (C9085, J3490, J3590), Saphnelo (C9086, J3490, J3590), Tezspire (C9399, J3490, J3590), Enjaymo (C9399** J3490**, J3590**), and Leqvio (C9399, J3490, J3590). Updated HCPCS code for Evkeeza to J1305.

October 2021: Criteria change: Expanded policy to include the following restricted products: Benlysta, Crysvisa, Ilaris, Cimzia, Adakveo, Vyepti, Evkeeza, Nulibry, Givlaari, Tremfya, Trogarzo, Uplizna, Prevymis, Oxlummo, Reblozyl, Onpattro, Ryplazim, Empaveli, NPlate, Evenity, Somatostatin Analogs, Tepezza, Ilumya, Stelara; added associated HCPCS/CPT codes: J0490, J0584, J0638, J0717, J0791, J3032, C9079, C9399, J3490, J3590, J0223, J1628, J1746, J1823, J0224, J0896, J0222, J2796, J3111, J2354, J2353, J2502, J1930, J3241, J3245, J3357, J3358. Corrected restricted products and codes for clarity to include: Asceniv, Fasenra, Radicava, and Ultomiris with associated codes J1554, J0517, J1301, and J1303; medical policy formatting change. **Policy notification given 8/2/2021 for effective date 10/1/2021.**

*Further historical criteria changes and updates available upon request from Medical Policy and/or Corporate Pharmacy.

Non-Discrimination and Accessibility Notice

Discrimination is Against the Law

- Blue Cross and Blue Shield of North Carolina (“Blue Cross NC”) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.
- Blue Cross NC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Blue Cross NC:

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
 - Qualified interpreters
 - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
 - Qualified interpreters
 - Information written in other languages
- If you need these services, contact Customer Service **1-888-206-4697**, TTY and TDD, call **1-800-442-7028**.
- If you believe that Blue Cross NC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
 - Blue Cross NC, PO Box 2291, Durham, NC 27702, Attention: Civil Rights Coordinator- Privacy, Ethics & Corporate Policy Office, Telephone **919-765-1663**, Fax **919-287-5613**, TTY **1-888-291-1783** civilrightscoordinator@bcbsnc.com
- You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, Civil Rights Coordinator - Privacy, Ethics & Corporate Policy Office is available to help you.
- You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 **1-800-368-1019, 800-537-7697** (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

- This Notice and/or attachments may have important information about your application or coverage through Blue Cross NC. Look for key dates. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call Customer Service **1-888-206-4697**.

ATTENTION: If you speak another language, language assistance services, free of charge, are available to you. Call 1-888-206-4697 (TTY: 1-800-442-7028).

ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-888-206-4697 (TTY: 1-800-442-7028).

注意: 如果您講廣東話或普通話, 您可以免費獲得語言援助服務。請致電 1-888-206-4697 (TTY : 1-800-442-7028) 。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-888-206-4697 (TTY: 1-800-442-7028).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-888-206-4697 (TTY: 1-800-442-7028)번으로 전화해 주십시오.

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-888-206-4697 (ATS : 1-800-442-7028).

ملحوظة: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1-888-206-4697. المبرقة الكاتبة: 1-800-442-7028.

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1-888-206-4697 (TTY: 1-800-442-7028).

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-888-206-4697 (телетайп: 1-800-442-7028).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-888-206-4697 (TTY: 1-800-442-7028).

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

સુચના: જો તમે ગુજરાતી બોલતા હો, તો નિ:સુલ્ક ભાષા સહાય સેવાઓ તમારા માટે ઉપલબ્ધ છે. ફોન કરો
1-888-206-4697 (TTY: 1-800-442-7028).

ចំណាំ: ប្រសិនបើលោកអ្នកនិយាយជាភាសាខ្មែរ សេវាកម្មជំនួយផ្នែកភាសាមានផ្តល់ជូនសម្រាប់លោកអ្នកដោយមិនគិតថ្លៃ។ សូមទំនាក់ទំនងតាមរយៈលេខ៖ 1-888-206-4697 (TTY: 1-800-442-7028)។

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-888-206-4697 (TTY: 1-800-442-7028).

ध्यान दें: यदि आप हिन्दी बोलते हैं तो आपके लिए मुफ्त में भाषा सहायता सेवाएं उपलब्ध हैं। 1-888-206-4697 (TTY: 1-800-442-7028) पर कॉल करें।

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1-888-206-4697 (TTY: 1-800-442-7028).

注意事項: 日本語を話される場合、無料の言語支援をご利用いただけます。1-888-206-4697 (TTY: 1-800-442-7028) まで、お電話にてご連絡ください。